Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis

Hematol Oncol. 2016 Mar;34(1):55-7. doi: 10.1002/hon.2174. Epub 2014 Oct 13.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acute Kidney Injury / etiology
  • Acute Kidney Injury / therapy
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Cell Division
  • Cyclophosphamide / therapeutic use
  • Cytokines / blood*
  • Drug Resistance
  • Granzymes / analysis
  • Humans
  • Killer Cells, Natural / drug effects*
  • Killer Cells, Natural / immunology
  • Lymphocyte Activation
  • Lymphocyte Count
  • Lymphohistiocytosis, Hemophagocytic / blood
  • Lymphohistiocytosis, Hemophagocytic / complications
  • Lymphohistiocytosis, Hemophagocytic / drug therapy*
  • Lymphohistiocytosis, Hemophagocytic / immunology
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Renal Replacement Therapy
  • Respiration, Artificial
  • Respiratory Insufficiency / etiology
  • Respiratory Insufficiency / therapy
  • Salvage Therapy*
  • T-Lymphocyte Subsets / drug effects*
  • T-Lymphocyte Subsets / enzymology
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocytes, Cytotoxic / drug effects
  • T-Lymphocytes, Cytotoxic / enzymology
  • T-Lymphocytes, Cytotoxic / immunology

Substances

  • Antibodies, Monoclonal, Humanized
  • Cytokines
  • Cyclophosphamide
  • Granzymes
  • tocilizumab
  • Methylprednisolone